Eli Lilly Boosts FY24 Outlook - Update
(RTTNews) - While reporting financial results for the first quarter on Tuesday, drugmaker Eli Lilly and Co. (LLY) raised its earnings, adjusted earnings and revenue guidance for the full-year 2024, primarily driven by the strong performance of Mounjaro and Zepbound and greater visibility into the company's production expansion for the remainder of the year.
For fiscal 2024, Eli Lilly now projects earnings in a range of $13.05 to $13.55 per share and adjusted earnings in a range of $13.50 to $14.00 per share on revenues between $42.4 billion and $43.6 billion.
Previously, the company expected earnings in the range of $11.80 to $12.30 per share and adjusted earnings in the range of $12.20 to $12.70 per share on revenues between $40.4 billion and $41.6 billion.
On average, 25 analysts polled by Thomson Reuters expect the company to report earnings of $12.50 per share on revenues of $41.44 billion for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
Eli Lilly Q2 Results Top Estimates; Boosts FY24 Outlook
Eli Lilly Again Boosts FY24 Outlook - Update
Eli Lilly Collaborates With OpenAI To Use Generative AI To Invent Novel Antimicrobials
Eli Lilly CFO Anat Ashkenazi Resigns
Lilly Says Phase 3 Trials Of Once-weekly Insulin In Type 2 Diabetes Meets Primary Endpoint
Eli Lilly Q4 Results Top Estimates
Eli Lilly Guides FY24 Revenues Above Estimates - Update
